The company also announced that two ongoing studies of its investigational adeno-associated virus (AAV)-based gene therapies, ABO-102 and ABO-101 have continued to treat patients, with additional enrollment expected in the programs in the coming weeks.Some better-ranked stocks in the biotech sector are Emergent Biosolutions Inc. EBS, Bristol Myers Squibb Company BMY and BioMarin Pharmaceuttical Inc. BMRN, all carrying a Zacks Rank #1 (Strong Buy).